13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002038158
Total reported value
$217.4M
$217.4M
24 檔
48.5%
During the Q1 2026 filing period, NEXTBio Capital Management LP (CIK: 0002038158) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $217.4M across 24 reported positions.
In Q1 2026, NEXTBio Capital Management LP displayed an active expansion posture, initiating 1 new positions and adding to 9 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 14.80% | -14.80% | EXIT | |
| 2 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 11.24% | +1.13% | — | |
| 3 | STTK | Shattuck Labs Inc | Stock-Other | 9.40% | +2.50% | — | |
| 4 | VOR | Vor Biopharma Inc | Stock-Other | 8.28% | -0.75% | — | |
| 5 | CMPS | Compass Pathways PLC | Stock-Other | 5.19% | +6.37% | +168.58% | |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 5.09% | +1.64% | +86.54% | |
| 7 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.95% | +0.14% | -0.26% | |
| 8 | PVLA | Palvella Therapeutics Inc | Stock-Other | 4.79% | +1.53% | — | |
| 9 | ZBIO | Zenas Biopharma Inc | Stock-Other | 3.87% | +1.11% | +32.53% | |
| 10 | IVA | Inventiva SA - Adr | Stock-Other | 3.44% | -0.33% | +2.68% | |
| 11 | VSTM | Verastem Inc | Stock-Other | 3.22% | -0.92% | -0.04% | |
| 12 | ✓ | Crescent Biopharma Inc. | Stock-Other | 3.18% | -0.09% | — | |
| 13 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.08% | +0.44% | -14.96% | |
| 14 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.98% | +4.73% | +41.08% | |
| 15 | PCVX | Vaxcyte Inc | Stock-Other | 2.57% | +0.30% | -0.27% | |
| 16 | COGT | Cogent Biosciences Inc | Stock-Other | 2.34% | -0.01% | +36.91% | |
| 17 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.08% | -2.08% | EXIT | |
| 18 | EVMN | Evommune Inc | Stock-Other | 1.96% | -1.23% | -19.37% | |
| 19 | OCS | Oculis Holding AG | Stock-Other | 1.85% | -1.85% | EXIT | |
| 20 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.60% | — | +12.24% | |
| 21 | IRON | Disc Medicine Inc | Stock-Other | 1.56% | +0.21% | +23.09% | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.23% | -1.23% | EXIT | |
| 23 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.79% | -0.79% | EXIT | |
| 24 | ACET | Adicet Bio Inc | Stock-Other | 0.50% | +0.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | STTK | Shattuck Labs Inc | +2.7% | — | Unchanged |
| 2 | CMPS | Compass Pathways PLC | +2.1% | +168.58% | Add |
| 3 | 430 | Terns Pharmaceuticals Inc | +1.7% | +9.68% | Add |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | +0.9% | +86.54% | Add |
| 5 | VOR | Vor Biopharma Inc | +0.6% | — | Unchanged |
| 6 | ✓ | Crescent Biopharma Inc. | +0.6% | — | Unchanged |
| 7 | COGT | Cogent Biosciences Inc | +0.3% | +36.91% | Add |
| 8 | ORIC | Oric Pharmaceuticals Inc | +0.1% | -14.96% | Trim |
| 9 | XENE | Xenon Pharmaceuticals Inc | +0.1% | -0.26% | Trim |
| 10 | OCS | Oculis Holding AG | +0.1% | -0.11% | Trim |
| 11 | PCVX | Vaxcyte Inc | 0% | -0.27% | Trim |
| 12 | 4XC1 | Kalvista Pharmaceuticals Inc | 0% | — | Unchanged |
| 13 | ZLAB | Zai Lab Ltd-adr | -0.1% | +12.24% | Add |
| 14 | IVA | Inventiva SA - Adr | -0.1% | +2.68% | Add |
| 15 | ACET | Adicet Bio Inc | -0.3% | — | Unchanged |
| 16 | PVLA | Palvella Therapeutics Inc | -0.3% | — | Unchanged |
| 17 | EVMN | Evommune Inc | -0.3% | -19.37% | Trim |
| 18 | IRON | Disc Medicine Inc | -0.4% | +23.09% | Add |
| 19 | PTGX | Protagonist Therapeutics Inc | -0.5% | — | Unchanged |
| 20 | GPCR | Structure Therapeutics Inc | -0.9% | +41.08% | Add |
| 21 | CMPX | Compass Therapeutics Inc | -1.4% | -23.86% | Trim |
| 22 | VSTM | Verastem Inc | -2.7% | -0.04% | Trim |
| 23 | ZBIO | Zenas Biopharma Inc | -3% | +32.53% | Add |
| 24 | SMMT | Summit Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, NEXTBio Capital Management LP reported a total U.S. public equity portfolio value of $217.4M across 24 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, PTGX, STTK) accounted for 48.5% of total reported equity market value during Q1 2026.
Top New Position Initiated
SMMT
市值: $1.7M
Top Position Liquidated / Trimmed
VSTM
前期市值: $10.1M
During Q1 2026, NEXTBio Capital Management LP's top holdings by market value included 430 (14.8%)、PTGX (11.2%)、STTK (9.4%). The largest single position, 430, represented 14.8% of total portfolio value.
In Q1 2026, NEXTBio Capital Management LP made 17 total portfolio adjustments, initiating 1 new buys, adding to 9 positions, trimming 7 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.